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O ne-lung ventilation (OlV) is a standard method that allows selective exclusion of one lung during 
anesthesia to assist the surgeon with his or her procedure. 
However, this method is associated with hypoxia and isch-
emia in the nonventilated lung tissue. upon reventilation, 
the deflated lung is reoxygenated, which triggers a well-
characterized hypoxia–reoxygenation injury similar to isch-
emic organ damage.
Patients undergoing lung surgery need general anesthesia 
with either a volatile (isoflurane, sevoflurane, and desflurane) 
or an intravenous anesthetic such as propofol. The choice 
between the different regimens for anesthesia maintenance 
What We Already Know about This Topic
•	 Recovery	 from	surgery	 involving	one-lung	ventilation	can	be	
complicated	 by	 acute	 pulmonary	 inflammatory	 processes.	
Some	data	suggest	 that	 such	 injury	might	be	 less	 if	 volatile	
(vs.	intravenous)	anesthesia	is	used.	It	was	hypothesized	that	
clinical	outcome	can	be	influenced.
What This Article Tells Us That Is New
•	 Four	hundred	and	sixty	patients	(five	centers)	undergoing	one-
lung	 ventilation	during	 thoracic	 surgery	were	 randomized	 to	
receive	either	propofol	or	desflurane.	There	was	no	difference	
in	major	complications	between	the	two	groups.
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ABSTRACT
Background: One-lung ventilation during thoracic surgery is associated with hypoxia–reoxygenation injury in the deflated 
and subsequently reventilated lung. numerous studies have reported volatile anesthesia–induced attenuation of inflammatory 
responses in such scenarios. If the effect also extends to clinical outcome is yet undetermined. We hypothesized that volatile 
anesthesia is superior to intravenous anesthesia regarding postoperative complications.
Methods: Five centers in Switzerland participated in the randomized controlled trial. Patients scheduled for lung surgery with 
one-lung ventilation were randomly assigned to one of two parallel arms to receive either propofol or desflurane as general 
anesthetic. Patients and surgeons were blinded to group allocation. Time to occurrence of the first major complication accord-
ing to the Clavien-Dindo score was defined as primary (during hospitalization) or secondary (6-month follow-up) endpoint. 
Cox regression models were used with adjustment for prestratification variables and age.
Results: Of 767 screened patients, 460 were randomized and analyzed (n = 230 for each arm). Demographics, disease and 
intraoperative characteristics were comparable in both groups. Incidence of major complications during hospitalization was 
16.5% in the propofol and 13.0% in the desflurane groups (hazard ratio for desflurane vs. propofol, 0.75; 95% CI, 0.46 to 
1.22; P = 0.24). Incidence of major complications within 6 months from surgery was 40.4% in the propofol and 39.6% in the 
desflurane groups (hazard ratio for desflurane vs. propofol, 0.95; 95% CI, 0.71 to 1.28; P = 0.71).
Conclusions: This is the first multicenter randomized controlled trial addressing the effect of volatile versus intravenous 
anesthetics on major complications after lung surgery. no difference between the two anesthesia regimens was evident. 
(A nesthesiology 2016; XXX:00-00)
B.B.-S. and J.M.B. contributed equally as first authors. M.F. and M.P. contributed equally as last authors.
Submitted for publication October 13, 2015. Accepted for publication April 13, 2016. From the Institute of Anesthesiology (B.B.-S., J.M.B.) 
and Department of Thoracic Surgery (W.W., D.S.), University Hospital Zurich, Zurich, Switzerland; Institute of Physiology, Zurich Center for 
Integrative Human Physiology (B.B.-S.), and Epidemiology, Biostatistics and Prevention Institute ( J.B., M.P.), University of Zurich, Zurich, 
Switzerland; Department of Anesthesiology, University of Illinois College of Medicine, Chicago, Illinois (B.B.-S.); Department of Anesthesia, 
Surgical Intensive Care, Prehospital Emergency Medicine and Pain Therapy, University Hospital Basel, Basel, Switzerland (M.S.); Depart-
ment of Anesthesiology and Intensive Care Medicine, Kantonsspital Muensterlingen (Cantonal Hospital of Muensterlingen), Muensterlingen, 
Switzerland (T.A.N., T.J.R.); Department of Anesthesiology and Pain Medicine, University Hospital Bern, Bern, Switzerland (F.S., A.V.); and 
Division of Anesthesiology, Intensive Care, Rescue and Pain Medicine, Kantonsspital St. Gallen (Cantonal Hospital of St. Gallen), St. Gallen, 
Switzerland (M.F.). Current position: Institute of Anesthesia and Intensive Care, Klinik Hirslanden Zurich, Zurich, Switzerland (M.S.).
Which Anesthesia Regimen Is Best to Reduce  
Morbidity and Mortality in Lung Surgery?  
A Multicenter Randomized Controlled Trial
Beatrice	Beck-Schimmer,	M.D.,	John	M.	Bonvini,	M.D.,	Julia	Braun,	Ph.D.,	Manfred	Seeberger,	M.D.,	
Thomas	A.	Neff,	M.D.,	Tobias	J.	Risch,	M.D.,	Frank	Stüber,	M.D.,	Andreas	Vogt,	M.D.,		
Walter	Weder,	M.D.,	Didier	Schneiter,	M.D.,	Miodrag	Filipovic,	M.D.,	Milo	Puhan,	M.D.,	Ph.D.
PeRIOPeRATIVe MeDICIne
PERIOPERATIVE MEDICINE
Copyright © 2016, the American Society of Anesthesiologists, Inc. Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.<zdoi;10.1097/ALN.0000000000001164>
Anesthesiology 2016; XXX:00-00 2 Beck-Schimmer et al.
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(volatile vs. intravenous) is mostly based on the anesthesi-
ologists’ habits and hospital practices. There is no evidence 
supporting superiority of the use of either a volatile or an 
intravenous anesthetic.
Because of the hypnotic effects of volatile anesthetics, 
attention has generally been focused on their use as general 
anesthetics. In the last decades, however, numerous studies 
have described an incremental value of volatile anesthetics: 
They provide protection to organs like the heart,1 liver,2,3 
lung,4,5 and kidney6 in the intraoperative period in situations 
of ischemia–reperfusion (hypoxia–reoxygenation)-induced 
tissue damage. Volatile anesthetics have been effectively used 
before or after the onset of injury (pre- or postconditioning),1 
but also during the entire surgical procedure (condition-
ing).7 All three volatile anesthetics isoflurane, sevoflurane, 
and desflurane have significantly decreased organ injury as 
expressed by biomarkers such as plasma levels of troponin,7,8 
transaminases,3,9 or inflammatory mediators in bronchoal-
veolar lavage fluid.4,5,10 Although these studies suggest that 
volatile anesthetics are immunomodulatory substances, it 
still has to be confirmed if they are potent enough to have an 
effect not only on biomarkers, but also on relevant clinical 
outcome parameters.
A large number of retrospective or prospective studies 
have already been performed, but all of them were clearly 
underpowered with regard to clinical outcomes. Our aim 
was to conduct the first adequately powered multicenter 
randomized controlled trial (RCT) to compare the effects of 
a volatile (desflurane) versus an intravenous anesthetic (pro-
pofol) on major complications during hospitalization and 
within the first 6 months after surgery in patients under-
going lung surgery with a well-defined hypoxia/ischemia 
period (OlV time) during surgery.
Materials and Methods
Study Design
This multicenter RCT was conducted in five thoracic sur-
gery centers in Switzerland, the university Hospitals of 
Zurich, Bern, and Basel and the Cantonal Hospitals of 
St. gallen and Muensterlingen. Patients enrolled were ran-
domly assigned to one of two parallel arms to receive either 
the intravenous anesthetic propofol (control group) or the 
volatile anesthetic desflurane (intervention  =  conditioning 
group) for lung resections performed either in open fashion 
or thoracoscopically.
The goal of this trial was to test the hypothesis of whether 
conditioning with desflurane leads to fewer major complica-
tions when compared to the control group during hospital-
ization (primary endpoint) and during the 6 months after 
lung resection surgery with OlV (secondary endpoint). We 
hypothesized that patients would experience fewer major 
complications during desflurane anesthesia.
The institutional boards approved this trial for human 
studies in all five centers (principal investigator and spon-
sor: university Hospital Zurich, Zurich, Switzerland, 
protocol KeK-ZH no. 2011-0092; Swissmedic notifica-
tion 2011DR4094). The study was registered at Clinical-
Trial.gov nCT01452256 and is reported according to the 
Consolidated Standards of Reporting Trials (COnSORT) 
statement.11 In all five centers, the Clinical Trial unit of the 
university of Zurich, Zurich, Switzerland, routinely moni-
tored the study. An interim analysis after inclusion of 150 
patients was performed by an independent data safety moni-
toring board.
Study Population
Patients were assessed for eligibility by the study team during 
routine preoperative visits between December 6, 2011, and 
March 28, 2014. All adults able to provide written informed 
consent, aged 18 to 80 yr, with American Society of Anes-
thesiologists physical status classification I to III and sched-
uled for elective lung resection surgery requiring OlV were 
eligible for study inclusion. exclusion criteria were known 
or suspected allergy to propofol, soy, or egg, as well as hyper-
sensitivity to volatile anesthetics (malignant hyperthermia). 
Therapy with cyclosporine or high dosages of statins as well 
as oral steroids (present or discontinued less than 3 months 
before surgery) was regarded as exclusion criteria. Patients 
suffering from severe renal impairment with a glomerular 
filtration rate less than 30 ml kg−1 min−1 1.73 m−2 and/or 
with inflammatory processes (nonpulmonary and pulmo-
nary), defined as increased C-reactive protein level (greater 
than 20 mg/l) or leukocytosis (leukocytes greater than 
10 × 103/μl) or body temperature greater than 37°C, were 
not included. Breast feeding, pregnancy, and intention to 
become pregnant over the following 60 days or lack of safe 
contraception in women of childbearing potential were also 
defined as exclusion criteria. Finally, patients involved in any 
other clinical trial within a period of 30 days before or 30 
days after completion of the current study were excluded.
Randomization
A web-based computerized and central randomization ser-
vice was used for the allocation of the participants (http://
www.randomizer.at). The minimization procedure ensured 
balanced groups (1:1 ratio) with respect to the number of 
patients in each arm and the three factors: center, number 
of comorbidities (coronary heart disease, chronic obstruc-
tive pulmonary disease, and mild to moderate renal impair-
ment defined as glomerular filtration rate of 30 to 59 ml kg−1 
min−1 1.73 m−2, chronic kidney disease), and pneumonec-
tomy. Patients were randomized immediately before enter-
ing the operating room or, if this was not possible, on the 
evening before surgery. Concealment of random allocation 
was ensured by the computerized and central randomization 
service.
Blinding
Patients and surgeons were blinded to group allocation 
throughout surgery and follow-up. Induction of anesthesia 
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was performed in a similar way in both groups. Propofol or 
desflurane were applied only after the patient lost conscious-
ness, thus making it impossible to know the correspondent 
arm of the study. Surgeons were blinded to the vaporizer 
or the propofol infusion by concealment of the respective 
device.
Anesthesia
Patients received oral premedication 30 min before anes-
thesia induction with midazolam. Standard monitoring 
(continuous 5-lead electrocardiogram, noninvasive blood 
pressure, and pulse oximetry) as well as bispectral index 
monitoring (Covidien, uSA) was installed in the induction 
room. Intravenous peripheral access was gained through a 
forearm vein. Cannulation of the radial artery was per-
formed before or immediately after anesthesia induction 
according to the clinical needs of the individual patient 
and at the discretion of the anesthesiologist. epidural 
anesthesia was indicated and performed following respec-
tive departmental guidelines. Central venous catheters 
were placed when deemed clinically necessary following 
respective departmental guidelines in each center. Crystal-
loids at a rate of 8 ml kg−1 h−1 were infused throughout the 
procedure. Colloid solution was applied when regarded as 
clinically necessary by the responsible anesthesiologist.
general anesthesia was induced in both groups with 0.3 
to 0.5 mg/kg etomidate (B. Braun Medical Ag, Switzerland); 
suppression of laryngoscopic stress response was achieved 
with intravenous application of 3 μg/kg fentanyl (Sintetica 
SA, Switzerland). 0.5 mg/kg atracurium (glaxoSmithKline 
Ag, Switzerland) or 0.6mg/kg rocuronium (Organon, Swit-
zerland) was applied to facilitate tracheal intubation. In the 
setting of a rapid-sequence induction, 0.9 mg/kg rocuronium 
or 0.8 mg/kg succinylcholine (Takeda Pharma Ag, Switzer-
land) was chosen.
In the propofol group (control), anesthesia was main-
tained using propofol (AstraZeneca Ag, Switzerland) at a 
rate of 4 to 10 mg kg−1 h−1 or as target-controlled infusion 
(2 to 6 µg/ml), while in the desflurane arm (intervention), 
desflurane (Baxter Ag, Switzerland) was applied with end-
tidal concentrations of 4.5 to 7.0%. Analgesia was achieved 
by applying boluses of fentanyl 1 to 2 μg/kg and/or con-
tinuous infusion of remifentanil (glaxoSmithKline Ag, 
Switzerland) up to 20 μg kg−1 h−1, according to the patient 
needs. Muscle relaxation was monitored with train-of-four 
stimulation of the ulnar nerve. When train-of-four response 
was two or more, 5 to 10 mg atracurium or rocuronium was 
readministered.
Ventilation
Ventilation was performed via double-lumen endotracheal 
tubes (different manufacturers) of sizes Ch35-41 accord-
ing to patient height. Right-sided tubes were preferred for 
left pneumonectomies or lung resections with left-sided 
lymphadenectomies.
During two-lung ventilation, settings were as follows: 
pressure-controlled mode; positive end-expiratory pressure, 
5 cm H2O; positive inspiratory pressure (PIP), less than 
or equal to 30 cm H2O; target-tidal volume, 6 to 8 ml/kg; 
inspiratory oxygen fraction (FIO2), 0.6 to 1.0 with target 
SpO2 greater than 90%; and respiratory rate, 10 to 20/min, 
with a target arterial carbon dioxide partial pressure of 33.7 
to 41.2 mmHg.
During OlV, settings were as follows: pressure-controlled 
mode, positive end-expiratory pressure, 5 cm H2O; PIP, less 
than 35 cm H2O; target-tidal volume, 4 to 6 ml/kg; FIO2, 0.6 
to 1.0, with target SpO2 greater than 90%; respiratory rate, 
10 to 20/min, with a target arterial carbon dioxide partial 
pressure of 33.7 to 41.2 mmHg. In case of hypoxia (SpO2 
less than 90% and PaO2 less than 60 mmHg), the follow-
ing strategies were implemented successively until sufficient 
oxygenation was achieved: (1) recruitment maneuver in the 
ventilated lung applying PIP, 40 cm H2O, for 10 s, (2) insuf-
flation of O2, 1 to 5 l/min, in the nonventilated lung, (3) 
continuous positive airway pressure, 5 cm H2O, in the non-
ventilated lung, and (4) reventilation of the collapsed lung.
For patients in the propofol group, an exit strategy 
switching the hypnotic to desflurane was implemented in 
patients with suspected anaphylactic reactions to propofol or 
its carrier substances and with hemodynamic instability, and 
for those with inadequate sedation despite high doses of pro-
pofol infusion. Protocol violations were noted, and patients 
in the randomized group were followed up according to the 
intention-to-treat principle.
Complications
Complications were assessed using the Clavien-Dindo classi-
fication with grade 0 (no complication) to grade V (death).12 
The Clavien-Dindo classification is widely used in surgical 
and anesthesiological research and captures the severity of 
complications by considering the intensity of the therapeu-
tic consequences. Complications graded I to II are defined 
as minor since they require only symptomatic postsurgi-
cal treatments (grade I, e.g., antiemetics or analgetics) or 
nonsurgical but more intensive treatments (grade II, e.g., 
blood transfusions). IIIa to V are major events comprising 
reinterventions without (grade IIIa) or with general anes-
thesia (grade IIIb), single-organ (grade IVa) or multiorgan 
failure (grade IVb), as well as all-cause mortality (grade V). 
This composite measure of complications has been used in 
hundreds of studies and is attractive since it overcomes the 
limitations of considering complications separately, which 
include the wide range of severity a specific complication 
may have and the insurmountable sample-size requirements. 
As it is standard, only the highest complication that patients 
experienced was analyzed.
To better reflect the fact that a patient could suffer from 
several complications, we also used the more recent com-
prehensive complication index (CCI)13 that considers all 
postsurgical complications as well as their severity on a scale 
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from 0 (no complication) to 100 (maximum burden from 
multiple complications). The CCI is more responsive to 
detect treatment effects than the traditional outcome (major 
complication yes/no).14
Complications were considered “related” when two dif-
ferent physicians who were blinded to group allocation 
independently determined potential causality relationship 
between lung resection surgery and major complication.
Endpoints
The primary study endpoint was the time to the occurrence 
of the first major complication (grade IIIa to V) during hos-
pitalization, while the time to the first major complication 
up to 6 months was defined as secondary endpoint. Further 
secondary endpoints were the time to the first major com-
plication related to lung resection during hospitalization and 
in the 6-month follow-up, CCI, and the length of intensive 
care unit and of the hospital stay.
Data Collection
Standardized web-based case report forms (secuTrial, inter-
Active Systems gmbH, germany) were used in all five cen-
ters to collect the data during surgery. An independent study 
nurse or anesthesiologist supervised data entry on a daily 
basis.
Complications were documented based on objective data 
such as (serum) markers or X-ray/computed tomography 
scan documentation. All major complications were recorded 
in the secuTrial. For the 6-month follow-up, the patient 
electronic chart system, which reliably provides information 
about the patient’s follow-up, was scanned again for any com-
plications. Additionally, family doctors/general practitioners 
of each patient were contacted by the local study team of the 
center and were systematically interviewed regarding com-
plications and the details of such events (standard letter). If 
the answer was not clear, a second inquiry was performed by 
phone. All complications were documented in the secuTrial 
in the same way as during the hospitalization period.
The study was officially monitored by the clinical trial 
unit of the university Hospital Zurich.
Sample Size Calculation
In a previous trial that compared sevoflurane and propo-
fol in patients undergoing liver surgery, we observed that 
anesthesia with sevoflurane decreased the risk of any major 
complications by more than 50%.3 Based on these data, and 
assuming that 20% of patients in the propofol group would 
experience a major complication during hospitalization (pri-
mary outcome) and 10% in the desflurane group, we esti-
mated that a sample size of 219 patients in each group would 
allow showing a relative risk of 2.0 with a power of 80% at 
a significance level of 5% (two-sided) (minimal sample size 
of 440) using a chi-square test. Assuming a drop-out rate 
of 10%, the sample size increased to 486. This sample size 
was also large enough to detect a hazard ratio (HR) of 2.0 
(minimal sample size of 96) or a HR of 1.5 (minimal sample 
size of 264).
Statistical Analysis
The nature of the analyses is based on the superiority of the 
intervention. We used descriptive statistics (median and inter-
quartile range [IQR] for continuous variables and percentages 
for categorical variables) to characterize the study population, 
the intervention and endpoints, stratified by group alloca-
tion. Kaplan–Meier curves were used to examine the time to 
occurrence of the first major complication in the two groups. 
For the comparison of time with regard to such complica-
tions between groups (any and related), we used a Cox pro-
portional hazard regression analysis with treatment allocation 
as independent variable. Cox models were calculated without 
further adjustment and additionally with adjustment for pres-
tratification variables and age. Similarly, we used linear regres-
sion analyses to compare the groups in terms of their CCI. 
Two-sided P values less than 0.05 were considered statistically 
significant. We conducted a number of prespecified subgroup 
analyses that included effect modification by age, the pres-
ence of a major disease, pneumonectomy, and OlV time. We 
assessed subgroup effects by introducing interactions with the 
treatment into the regression model and considered subgroup 
effects to be significant if P ≤ 0.10 because of the low power 
of interaction testing to detect subgroup effects. All analyses 
were performed with the statistics program R, version 3.2.0.15
Results
Patient Recruitment
Between December 6, 2011, and March 28, 2014, of 
767 patients undergoing lung resection with OlV who were 
screened for recruitment at the five Swiss study centers, a 
total of 465 patients were enrolled (fig. 1). Three hundred 
and two patients had to be excluded based on the following 
criteria: enrollment in other studies or missing willingness to 
participate. There were 5 patients (1.1%) who dropped out 
due to rejection for randomization. These patients had been 
enrolled before an exclusion criterion was identified.
According to the surgical volume of the center, 46 patients 
were randomized and analyzed in Basel, 70 in Bern, 27 in 
Muensterlingen, 120 in St. gallen, and 197 in Zurich—460 
patients in total with 230 subjects per arm as necessary 
according to the power analysis.
A change of the allocated procedure was necessary in one 
patient, but data were analyzed in an “intention-to-treat” 
manner based on the original allocation.
Patient Characteristics
no important difference between the propofol and desflu-
rane arm was observed, including the criteria age, sex, body 
mass index, American Society of Anesthesiologists classifi-
cation, diagnosis (benign and malignant), and preexisting 
major diseases (coronary heart disease, chronic obstructive 
pulmonary disease, and chronic kidney disease; table 1).
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Intraoperative Data
Intraoperative characteristics were comparable (table 1). Par-
ticularly, there was no difference between OlV time (mean 
of 155 [IQR, 78 to 245) min for propofol and 140 [IQR, 
58 to 241] min for desflurane) as well as the duration of 
surgery and anesthesia. Approximately 40% of the patients 
underwent thoracotomy (without pneumonectomy) in both 
groups. nine patients (4%) had a pneumonectomy in the 
propofol and seven (3%) in the desflurane groups. Overall, 
103 patients (45%) experienced major surgery in the propo-
fol and 98 (43%) in the desflurane groups. Blood loss and 
transfusion requirements were comparable in both groups 
(table 1).
Major Complications
Primary and Secondary Outcomes. Overall the proportion 
of patients experiencing at least one major complication 
during hospitalization (primary outcome) was 13% in the 
desflurane and 16.5% in the propofol groups (table 2). For a 
descriptive comparison of the time to occurrence of the first 
major complication during hospitalization, Kaplan–Meier 
curves are shown in figure 2A. Both in the unadjusted and in 
the adjusted Cox models, the difference between groups was 
not statistically significant (unadjusted HR, 0.77; 95% CI, 
0.47 to 1.24; P = 0.28; adjusted HR, 0.75; 95% CI, 0.46 to 
1.22; P = 0.24) (table 2).
Major complications within 6 months after surgery were 
40% (see also Kaplan–Meier curve in fig. 2B). Again no sig-
nificant difference between groups could be found (unad-
justed HR, 0.96; 95% CI, 0.72 to 1.28; P = 0.76; adjusted 
HR, 0.95; 95% CI, 0.71 to 1.28; P = 0.75) (table 2). When 
complications related to surgery were analyzed separately, 
results were similar (table  3) with no difference between 
groups.
The median CCI was 22.6 in the desflurane (IQR, 0 to 
37.9) and 26.0 in the propofol group (IQR, 8.7 to 39.5). 
There was no significant difference between groups for the 
CCI nor for all major complications during hospitaliza-
tion (P = 0.33) or over 6 months (P = 0.82), Again, we did 
not observe any statistically significant difference for study-
related complications during hospitalization (P = 0.78) or 
over 6 months (P = 0.53).
Finally, the length of intensive care unit (median of 
0 days [IQR, 0 to 1] in both groups; P = 0.21) and hospital 
stay (median of 8 days [IQR, 5 to 12] in the desflurane and 
median of 7.5 days [IQR, 5 to 11] in the propofol group; 
P = 0.52) did not differ between groups, either.
Subgroup Analyses. none of the prespecified variables sug-
gested a subgroup effect. Interaction terms were not statisti-
cally significant for age (P = 0.22 for interaction term during 
hospitalization and P = 0.59 for 6-month follow-up), the 
presence of a major disease (P = 0.29 for interaction term 
during hospitalization and P = 0.75 for 6-month follow-up), 
pneumonectomy (P = 0.80 for interaction term during hos-
pitalization and P = 0.74 for 6-month follow-up), or OlV 
time (P = 0.92 for interaction term during hospitalization 
and P = 0.19 for 6-month follow-up).
Discussion
Promising results from clinical trials have emerged, showing 
that expression of inflammatory mediators is less pronounced 
after pulmonary ischemia–reperfusion in the presence of 
Fig. 1. Enrollment of patients. Of note is that one patient of the propofol group was anesthetized with desflurane; however, the 
patient was evaluated in an intention-to-treat manner as a propofol patient.
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volatile anesthetics. Based on the suggestions of potential 
clinical benefit, we performed the first large and adequately 
powered multicenter RCT to address the effect of volatile 
anesthetics on major complications after lung surgery. no 
significant difference was observed between the volatile and 
intravenous anesthesia regimen, and complication rate was 
comparable. The proportion of patients with complications 
was similar.
Clinical studies on anesthesia in lung surgery revealed 
that volatile anesthetics decrease pulmonary inflammation 
in the deflated-reoxygenated operated or the nonoperated 
lung, based on surrogate markers.4,5,10 One of our former 
trials also suggested improved clinical outcomes4 but was 
not powered for a strong endpoint such as major complica-
tions. The current study includes an appropriate number of 
patients and demonstrates unequivocally that organ protec-
tion is not significant enough to have an impact on measur-
able clinical outcomes.
Several explanations for our findings may be given. At 
the same time, these considerations also highlight the limita-
tions of the trial. One might argue that desflurane should 
have been given for pre- or postconditioning, while we have 
applied desflurane during the entire surgical procedure. We 
believe, however, that with OlV, the anesthetic supply to the 
deflated lung is interrupted and therefore comparable to a 
pre- or postconditioning scenario. Additionally, we intended 
to use a protocol that can be performed without the need for 
additional communication between the surgeon and the anes-
thesiologist, which may prolong the procedure unnecessarily.
Another explanation for our finding may be the type of 
the volatile anesthetic chosen, desflurane. However, desflu-
rane just like sevoflurane has actually been shown to provide 
protection in ischemia–reperfusion-like injury.7,16 Former in 
vitro and in vivo studies from our group have highlighted 
that fluorinated carbon groups in all volatile anesthetics may 
be responsible for the protection.17,18 While sevoflurane 
consists of two such groups, only one is present in desflu-
rane. However, since the alveolar desflurane concentration 
required for deep anesthesia is at least three times as high as 
that of sevoflurane, desflurane might therefore provide simi-
lar amounts of protective fluorinated groups to the alveoli.
Another explanation concerns the degree of injury 
incurred by thoracic surgery and whether it is too little to 
allow us to detect a protection from injury at all. Compared 
to former studies in liver surgery,3,9 where we clearly found 
a positive impact of volatile anesthetics on major complica-
tions, the rate of serious adverse events in thoracic surgery 
seems certainly lower, which is also underlined by other 
studies.19 This suggests the explanation that protection is 
not effective when relevant injury is missing. We recently 
performed a large multicenter study with similar findings 
in liver transplant patients.20 Increase of transaminases after 
reperfusion was mild, with a peak median aspartate amino-
transferase of only 1,000 u/l and an alanine aminotransferase 
of only 750 u/l. This study did not even show a difference 
of the primary endpoint (peak transaminases) between sevo-
flurane and propofol anesthesia. Yet another study in line 
with these negative findings is the multicenter clinical trial, 
which has been performed in patients at high cardiac risk 
undergoing noncardiac surgery, randomizing 385 patients to 
either sevoflurane or propofol anesthesia.21 The incidence of 
Table 1. Baseline Characteristics of Patients and Intraoperative 
Parameters for Propofol and Desflurane Groups
Propofol 
(n = 230)
Desflurane  
(n = 230)
Age (yr), median (IQR) 65 (57–70) 63 (54–70)
Sex: male, n (%) 144 (63) 145 (63)
BMI (kg/m2), median (IQR) 25 (23–28) 25 (22–29)
ASA, n (%)
  I 12 (5) 13 (6)
  II 107 (47) 116 (50)
  III 107 (47) 99 (43)
  IV 3 (1) 2 (1)
Diagnosis, n (%)
  Benign lesion 50 (22) 53 (23)
  Malignant lesion 180 (78) 177 (77)
CHD, n (%)
  No 196 (87) 201 (89)
  Yes 30 (13) 26 (11)
COPD, n (%)
  No 151 (66) 157 (68)
  Yes 79 (34) 73 (32)
Diabetes, n (%)
  No 203 (88) 209 (91)
  Yes 27 (12) 21 (9)
CKD, n (%)
  No 205 (89) 208 (91)
  Yes 24 (11) 21 (9)
Major disease, n (%)
  0 119 (52) 133 (58)
  1 87 (38) 71 (31)
  2 22 (10) 21 (9)
  3 2 (1) 5 (2)
OLV time (min), median (IQR) 155 (78–245) 140 (58–241)
Surgery time (min),  
median (IQR)
215 (110–309) 205 (105–300)
Anesthesia time (min),  
median (IQR)
333 (237–440) 330 (230–440)
Procedures, n (%)
  Thoracoscopy 127 (55) 132 (57)
  Thoracotomy 94 (41) 91 (40)
  Pneumonectomy 9 (4) 7 (3)
Blood loss (ml), median (IQR) 100 (20–250) 100 (30–200)
Patients with transfusion, n (%)
  No 226 (98) 227 (99)
  Yes 4 (2) 3 (1)
The following data were missing: American Society of Anesthesiologists 
(ASA) classification for one patient in the propofol group; coronary heart 
disease (CHD) of four patients in the propofol and of three patients in the 
desflurane group; one patient for both groups with regard to chronic kidney 
disease (CKD). ASA IV: Although being an exclusion criterion, this classi-
fication was chosen by the responsible anesthesiologist, which obviously 
was in discrepancy to the first evaluation.
BMI = body mass index; COPD = chronic obstructive pulmonary disease; 
IQR = interquartile range; OLV = one-lung ventilation.
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myocardial ischemia was similar in both groups at 40%, and 
the Q-wave infarction rate was 0.5%.
One could also raise the concern or claim a limitation 
of the trial that we did not exclusively focus on respiratory 
complications after thoracic surgery. Our goal was to use a 
composite measure of complications, which allows compari-
son with hundreds of other study results using the same scor-
ing system. Also the Clavien-Dindo classification is of high 
clinical relevance as it was established based on the treatment 
consequences a complication has.
A surgical procedure, which evokes numerous major com-
plications, is pneumonectomy.22 Thanks to the advances in 
diagnostic and screening methods, the incidence of patients 
needing such an invasive procedure was low. We included 
seven patients undergoing pneumonectomy in the desflu-
rane and nine in the propofol arms. In the pneumonectomy 
subgroup, there were four complications in the desflurane 
group, one of minor and three of major grade (1xII, 2xIIIa, 
and 1xIIIb), and 18 complications were found in the pro-
pofol group (nine of minor and nine of major grade: 2xI, 
Table 2. Comparisons of Incidence of Major Complications (Any Events) for Propofol and Desflurane Groups
Propofol  
(n = 230)
Desflurane 
(n = 230)
Unadjusted Incidence 
Rate Ratio
Adjusted Incidence  
Rate Ratio*
Incidence of major complications  
during hospitalization:
  Overall (%)
  Overall per 100 person-days
38 (16.5)
0.402
30 (13.0)
0.348
0.77
(95% CI, 0.47–1.24; 
P = 0.28)
0.75
(95% CI, 0.46–1.22;  
P = 0.24)
Incidence of all major complications up 
to 6 months follow-up:
  Overall (%) 93 (40.4) 91 (39.6) 0.96
(95% CI, 0.72–1.28;  
P = 0.76)
0.95
(95% CI, 0.71–1.28;  
P = 0.75)
*Adjusted for prestratification variables (study cite, major disease, and pneumonectomy) and age.
Fig. 2. Kaplan–Meier survival curves, not adjusted for covariates. They represent occurrence of the first major complication after 
lung surgery, (A) during hospitalization and (B) within 6 months.
Table 3. Comparisons of Incidence of Related Major Complications for Propofol and Desflurane Groups
Propofol 
(n = 230)
Desflurane 
(n = 230)
Unadjusted Incidence Rate 
Ratio
Adjusted Incidence 
Rate Ratio*
Incidence of related major  
complications during hospitalization:
 Overall (%) 22 (9.6) 20 (8.7) 0.94 (95% CI, 0.52–1.73; 
P = 0.85)
0.94 (95% CI, 
0.51–1.74; P = 0.85)
Incidence of related major  
complications up to 6 months follow-up:
 Overall (%) 33 (14.3) 36 (15.7) 1.10 (95% CI, 0.68–1.76;  
P = 0.70)
1.09 (95% CI,  
0.68–1.76; P = 0.71)
*Adjusted for prestratification variables (study cite, major disease, and pneumonectomy) and age.
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7xII, 1xIIIa, 2xIIIb, 4xIVa, and 2xV). Similar results were 
observed for the 6-month follow-up period with seven 
minor and three major events (3xI, 4xII, 2xIIIa, and 1xIIIb) 
in the desflurane and 12 and 11, respectively, in the propofol 
group (2xI, 10xII, 3xIIIa, 2xIIIb, 4xIVa, 2xV). The mortal-
ity rate of these pneumonectomy patients in the 6-month 
follow-up was 2/9 in the propofol group, while there was no 
mortality found in the desflurane group. The relevance of 
this subgroup analysis is unclear, and this finding should not 
be overemphasized but warrants future studies focusing on 
patients with higher severity of injury like those undergoing 
pneumonectomy.
even though this trial presents negative results, these find-
ings should not be ignored. Once more, results of small and 
large retrospective studies with their intrinsic biases extensively 
demonstrate protective effects, while an adequately powered 
randomized study cannot confirm these findings. It may well 
be that only patients with severe injuries benefit from the fre-
quently invoked antiinfammatory effects of volatile anesthetics.
In summary, this is the first adequately powered RCT 
showing that desflurane compared to propofol anesthesia 
does not reduce the number of short- and long-term major 
complications after standard lung surgery. equivalence 
of both regimens can now be confidently established in 
anesthetic management protocols.
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